The New Reality
Five years ago, most protein sourcing conversations focused on price per milligram and delivery timelines. Today, the conversation has shifted. The question is no longer just “Can you supply it?” but “Will you still be able to supply it—consistently and predictably—next year?”
The reasons are well documented. COVID-19 disrupted biological source material collection worldwide. Plasma centers operated at reduced capacity. Tissue procurement slowed. For native protein manufacturers who depend on human and animal biological materials, these disruptions rippled through production schedules for months.
But the pandemic was only the beginning.
Geopolitical tensions have introduced a second wave of uncertainty. Tariff volatility between major trading blocs has caused some customers to pause orders entirely, waiting for clarity that may not come. The BIOSECURE Act—targeting certain foreign biotechnology companies—is pushing life sciences organizations to reassess supply chain dependencies they once considered stable. Supplier selection decisions that were previously based simply on cost and availability are now being influenced by legislative and policy pressures.
The data confirms what many procurement teams already sense. Supply chain disruption alerts in healthcare increased 40% year-over-year in early 2024. Price fluctuations of 25–30% have hit key reagent categories. And a stark geographic concentration persists: over 60% of critical raw materials for reagent production originate from just three countries.
For organizations that use protein reagents in diagnostic assays, cell culture media, or pharmaceutical manufacturing, these aren’t abstract risks. A single missing reagent can halt a production line, delay a product launch, or compromise a clinical study. When downstream products support patient care or regulated manufacturing, supply continuity becomes both a business imperative and a compliance concern.
Five Vulnerabilities Hiding in Your Supply Chain
Most organizations don’t discover supply chain weaknesses until something breaks. Here are the five most common vulnerabilities we see across the life sciences industry—and the questions that reveal them.
1. Single-Source Dependency
Relying on one supplier for a critical reagent is the most common and most dangerous vulnerability. It persists because switching costs are high—particularly for IVD manufacturers, where qualifying a new reagent source can take 12–18 months of validation work.
But the risk is real. Suppliers exit markets. Products get discontinued. Production issues arise. When your sole supplier encounters a problem, your options narrow to emergency sourcing at premium prices—or shutting down production while you scramble to qualify an alternative.
The test: For each critical protein in your workflow, can you name a qualified backup supplier? If not, you have single-source exposure.
2. Offshore Manufacturing Opacity
Many protein suppliers outsource production to contract manufacturing organizations, sometimes across multiple geographies. When your supplier’s supplier has a problem, you may not learn about it until your order is already delayed.
Offshore manufacturing also introduces regulatory and geopolitical risk. Export controls, tariff changes, and legislative actions like the BIOSECURE Act can disrupt established supply relationships with little warning. Organizations that lack visibility into where reagents are physically manufactured—not just where they are shipped from—are especially exposed.
The test: Do you know where your protein reagents are physically manufactured and whether production is in-house or outsourced?
3. Inadequate Quality Documentation
A Certificate of Analysis should be a trust document—proof that a specific lot meets defined specifications. Too often, it’s a generic template with boilerplate numbers that haven’t changed across lots.
This matters beyond quality assurance. Under EU IVDR and FDA Quality System Regulation, manufacturers must document their supplier qualification rationale. Lot-specific analytical data—such as actual gel images, quantified purity values, and activity measurements—provides the evidence trail that auditors expect. Generic documentation creates regulatory exposure.
The test: Does your supplier’s CoA include lot-specific analytical data (gel images, densitometry, activity assays)—or only repeated specification ranges?
4. No Forward Supply Planning
Spot buying—placing orders only when inventory is nearly depleted—can work in stable markets. In volatile markets, it leaves buyers competing for limited supply with no priority or protection.
For IVD and cell culture media manufacturers with predictable consumption patterns, the alternative is forward planning: sharing forecasts with suppliers, reserving specific lots in advance, and establishing agreements that guarantee access during tight markets.
Importantly, forecasting does not require a binding purchase commitment. It provides suppliers with the visibility needed to plan production responsibly, allocate capacity, and maintain lot continuity. Organizations that plan ahead don’t just avoid stock-outs—they also secure lot consistency across long production runs.
The test: Do you have lot reservation or forward-planning agreements with critical suppliers, or are purchases made strictly on a per-order basis?
5. Transactional Supplier Relationships
When your relationship with a supplier consists entirely of purchase orders and invoices, you have no early warning system. You won’t hear about upcoming product changes, raw material constraints, or capacity limitations until they directly affect your order.
By contrast, suppliers that function as partners provide advance notice of changes, collaborate on formulation challenges, and invest in understanding applications well enough to anticipate issues before they reach the bench—or the production line.
The test: When you contact your supplier with a technical question, do you reach a scientist—or a customer service queue?
A Framework for Supply Chain Resilience
Identifying vulnerabilities is the first step. Building resilience requires a structured approach across five dimensions.
Pillar 1: Diversify Suppliers
Objective: Eliminate single-source dependencies for critical reagents.
Supplier diversification doesn’t mean splitting orders between interchangeable vendors. For protein reagents—particularly in IVD applications where each new source requires validation—it means proactively qualifying a second supplier so that if your primary source encounters difficulties, you can transition without starting from zero.
The cost of maintaining a qualified backup is modest compared to the cost of emergency sourcing. A planned qualification takes months. An emergency qualification, under production pressure, takes just as long—but with the added cost of delayed shipments and potential regulatory findings.
Key actions:
- Qualify at least two suppliers for each critical protein
- Maintain validation data for both sources
Pillar 2: Require Manufacturing Transparency
Objective: Know exactly where and how your reagents are produced.
Ask the question directly: is this protein manufactured in your own facility, or outsourced to a contract manufacturer? If outsourced, where?
In-house manufacturing provides shorter feedback loops between quality control and production, greater control over raw material sourcing, and reduced exposure to the cascading risks that arise when multiple organizations are involved in a single product’s manufacture. It also simplifies regulatory traceability—a growing requirement under EU IVDR and FDA expectations for component suppliers.
Key actions:
- Require disclosure of manufacturing location and in-house vs. CMO status
- Verify quality certifications for each manufacturing site
Pillar 3: Demand Documentation Rigor
Objective: Ensure lot-level traceability and analytical evidence.
A meaningful Certificate of Analysis should tell you exactly what was tested, on which lot, using what methods, and what the results were. Not just that the product “met specifications.”
Look for lot-specific gel images (not generic representative images), quantitative purity data from methods like densitometry or HPLC, and activity or functional assay results where applicable. Endotoxin testing documentation is essential for any cell culture application. If your supplier can’t provide this level of detail, consider why.
Key actions:
- Require lot-specific CoAs with actual analytical data
- Verify testing methods match your quality requirements
Athens Bioscience provides lot-specific CoAs with SDS-PAGE gel images, densitometry quantification, and complete analytical data for every production lot.
Pillar 4: Plan Forward
Objective: Secure supply before you need it.
For organizations with predictable consumption—IVD manufacturers running established assays, cell culture media companies with stable formulations—forward planning dramatically reduces supply risk.
Lot reservation is one of the most effective tools. By identifying a lot that performs well and reserving it against future purchase orders, organizations reduce variability and secure availability. Some Athens customers have maintained reserved lots for multiple years, ensuring continuity across extended production campaigns.
Even when consumption is less predictable, sharing rolling forecasts—ideally in the context of a long-termy supply agreement—allows suppliers to align capacity and raw material sourcing accordingly. In constrained markets, suppliers inevitably prioritize customers who plan ahead.
Key actions:
- Share consumption forecasts with critical suppliers
- Negotiate lot reservations for high-use proteins
- Establish multi-year supply agreements for critical reagents
Pillar 5: Build Strategic Relationships
Objective: Turn suppliers into strategic partners with shared incentives.
The strongest supply chains aren’t just resilient by design—they’re resilient because the people on both sides of the relationship communicate openly and invest in mutual success.
This means direct access to scientists who understand your application, not just sales representatives taking orders. It means advance notice when a supplier is changing a process, discontinuing a product, or experiencing capacity constraints. And it means genuine collaboration on technical challenges—custom formulations, buffer optimization, scaling from research to production quantities.
The difference between a vendor and a partner often becomes apparent only when something goes wrong. By then, it’s too late to build the relationship you need.
Key actions:
- Establish scientist-to-scientist communication channels
- Conduct periodic business reviews with critical suppliers
- Share application context to enable proactive support
The Regulatory Dimension
Supply chain management is increasingly a regulatory issue—not just an operational one.
EU IVDR, FDA QSR, and ISO 13485 all emphasize supplier qualification, traceability, and documentation rigor. While Athens operates under an ISO 9001:2015 certified quality system, we support our IVD and cell-culture customers by providing the documentation and transparency required for their own ISO 13485 and regulatory compliance obligations.
Practically, this means your supplier documentation file should include: manufacturing location and method, quality system certifications, lot-specific Certificates of Analysis, evidence of incoming material controls, and documentation of any changes to manufacturing processes.
What to Ask Your Protein Supplier
Use these questions during supplier qualification or periodic review. A strong supplier should be able to answer all of them clearly and directly.
Manufacturing & Sourcing
- Where is the protein physically manufactured? Is production in-house or outsourced?
- What is the geographic origin of your raw/source materials?
- Do you have multiple qualified sources for your starting biological materials?
- What is your facility’s current quality system certification (ISO 9001, ISO 13485)?
Quality & Documentation
- Do your Certificates of Analysis include lot-specific analytical data or generic specifications?
- What purity methods do you use (SDS-PAGE, HPLC, densitometry, mass spectrometry)?
- Can you provide activity/functional assay data for each lot?
- What is your endotoxin testing methodology and specification?
Supply Continuity
- Do you offer lot reservation for long-term supply security?
- What is your standard lead time? What happens during high-demand periods?
- Can you scale from R&D quantities (mg) to production quantities (g to kg)?
- What is your policy for advance notification of product changes or discontinuations?
Technical Partnership
- Can I speak directly with a scientist about my application?
- Do you offer custom formulations (buffer, purity grade, endotoxin level, packaging)?
- What is your typical response time for technical inquiries?
Building Resilience: A 90-Day Action Plan
Supply chain resilience doesn’t require a multi-year transformation. These practical steps can meaningfully reduce your exposure within 90 days.
Days 1–30: Audit
Map your current protein supplier dependencies. For each critical reagent, document the supplier name, manufacturing location (if known), annual spend, whether a qualified backup exists, and current documentation on file. Identify your highest-risk items—those with single-source supply, high annual spend, or long qualification timelines.
Days 31–60: Evaluate
For high-risk items, request documentation packages from both existing and candidate suppliers. Compare against the supplier checklist above. Flag any supplier that cannot provide lot-specific analytical data or clear manufacturing location disclosure. Begin conversations with potential backup suppliers for your most critical reagents.
Days 61–90: Act
Initiate lot reservation agreements for proteins with predictable consumption. Request validation samples from candidate backup suppliers. Establish a supplier review calendar for periodic re-evaluation. Document your supply chain risk assessment—your quality system and auditors will thank you.
Resilience as Competitive Advantage
Supply chain management in life sciences has entered a new era. Organizations that invest early in supplier relationships, documentation rigor, and forward planning don’t just reduce risk—they outperform competitors.
While others scramble for alternatives and explain delays to their customers, resilient organizations maintain production schedules, meet regulatory expectations, and reinforce trust in the markets they serve.
That is what supply-chain resilience looks like in practice.
About Athens Bioscience, Inc.
Since 1985, Athens Bioscience, Inc. (formerly known as Athens Research & Technology) has been a global leader in native protein purification. We manufacture 170+ native human and animal proteins in our ISO 9001:2015 certified, 11,000 square foot facility in Athens, Georgia. Our proteins are cited in over 1,500 peer-reviewed publications and trusted by leading IVD manufacturers, cell culture media companies, and research institutions worldwide.
Contact:
U.S.: +1-706-546-0207 | sales@athensbioscience.com
Europe: +31-548-659-006 | europe@athensbioscience.eu